Mesupron (upamostat)

News alerts, weekly reports and conference planners

Company:

Heidelberg Pharma, RedHill

Drug class:

Serine protease inhibitor, Urokinase-type plasminogen activator inhibitor

Related drugs:

‹

›

5ms

Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease (clinicaltrials.gov)

P2/3, N=61, Terminated, RedHill Biopharma Limited | N=310 --> 61 | Suspended --> Terminated; Part A complete; corporate decision made to cancel Part B.

5 months ago

Enrollment change • Trial termination

Mesupron (upamostat)

8ms

Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts. (PubMed, Cancers (Basel))

Mouse weights and PAX165 tumor volumes were measured. Tumor volumes in the upamostat, opaganib, and upamostat plus opaganib groups were significantly decreased compared to the control group.

8 months ago

Journal

PRSS3 (Serine Protease 3) • PRSS1 (Serine Protease 1) • SPHK1 (Sphingosine Kinase 1)

Mesupron (upamostat) • WX-UK1 • Yeliva (opaganib)

9ms

PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19 (clinicaltrials.gov)

P2, N=300, Recruiting, Henry M. Jackson Foundation for the Advancement of Military Medicine | Not yet recruiting --> Recruiting

9 months ago

Enrollment open

Mesupron (upamostat)

2years

MECHANISTIC EFFECTS OF UPAMOSTAT AND OPAGANIB IN CHOLANGIOCARCINOMA CELL LINES (AASLD 2022)

Upamostat and its active metabolite WX-UK1 have been shown to inhibit serine proteases. Upamostat and opaganib in combination have significant inhibitory effects on both CCA cell migration and viability in vitro which may prevent tumor progression. Both drugs have an established clinical safety profile and may be effective in targeted treatment of CCA patients.

2 years ago

Preclinical

HER-2 (Human epidermal growth factor receptor 2)

Mesupron (upamostat) • WX-UK1 • Yeliva (opaganib)